Saniona: Receives its Second Orphan Drug Designation - Redeye
Redeye argues that the orphan drug designation is another progress and milestone for the company. It is also a testament to the active work Saniona conducts in the rare eating disorders space.
ANNONS
Redeye argues that the orphan drug designation is another progress and milestone for the company. It is also a testament to the active work Saniona conducts in the rare eating disorders space.
